BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...
Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...
Low-dose colchicine reduces not only MACE but also MI, stroke, and the need for coronary revascularization among patients with known CAD, according to a new meta-analysis that sought to better tease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results